Julie Krop Sells 25,000 Shares of Aquestive Therapeutics (NASDAQ:AQST) Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Director Julie Krop sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total value of $125,500.00. Following the completion of the transaction, the director directly owned 25,000 shares in the company, valued at approximately $125,500. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Trading Down 10.4%

AQST opened at $4.47 on Friday. The business has a 50 day moving average of $4.23 and a 200-day moving average of $4.39. The stock has a market capitalization of $560.76 million, a price-to-earnings ratio of -7.33 and a beta of 1.46. Aquestive Therapeutics, Inc. has a 1-year low of $2.93 and a 1-year high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. The company had revenue of $14.45 million for the quarter, compared to the consensus estimate of $10.90 million. Equities analysts predict that Aquestive Therapeutics, Inc. will post -0.41 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AQST shares. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Oppenheimer began coverage on Aquestive Therapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $8.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $8.50.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC acquired a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $28,000. BNP Paribas Financial Markets raised its position in Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares in the last quarter. Modern Wealth Management LLC acquired a new position in Aquestive Therapeutics in the second quarter worth about $33,000. Elevation Point Wealth Partners LLC bought a new position in Aquestive Therapeutics during the first quarter worth about $42,000. Finally, ADAR1 Capital Management LLC boosted its holdings in Aquestive Therapeutics by 103.9% during the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after purchasing an additional 264,000 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.